Table TDI-24. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2004: the combination of cannabis, opioids, cocaine or other stimulants as primary drug type with a secondary drug – Part (iii) All clients with cocaine as primary drug type: numbers reporting the stated drugs as secondary

Country

Opioids

Cocaine

Other stimulants

Hypnotics, sedatives

Hallucinogens

Volatile inhalants

Cannabis

Alcohol

Others

Total

Czech Republic

1

0

0

0

0

0

2

0

0

3

Germany

0

0

0

0

0

5

1088

758

26

1877

Greece

26

0

16

6

7

0

37

6

2

100

Italy

4495

0

1621

432

445

0

5716

3191

126

16026

Cyprus

6

0

11

1

5

0

17

3

0

43

Netherlands

0

0

0

0

0

1

635

956

24

1616

Slovakia

2

0

6

0

1

0

2

2

0

13

Finland

0

0

0

0

0

0

1

0

0

1

Sweden

0

0

0

0

0

0

0

0

0

0

United Kingdom

4428

790

2594

612

70

22

2426

548

38

11528

Bulgaria

0

0

0

0

0

0

0

1

0

1

 

 

 

 

 

 

 

 

 

 

 

Total

8958

790

4248

1051

528

28

9924

5465

216

31208

Notes: 

Data on secondary drug use are only collected for all treatment clients and not separately for new treatment clients.

Opioids include: heroin, methadone, other opioids; cocaine includes: cocaine CIH, crack cocaine; stimulants include: amphetamines, MDMA and derivates, other stimulants; cannabis can include herbal cannabis or cannabis resin. For each client up to four secondary drugs can be reported

A number of the clients report using the same drug both as primary and secondary drug, particularly for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI Protocol for the drugs categories.

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Source:

2005 Reitox national reports

Data filter | tditab24c-en.xml